Skip to Content

Join the 'Herpes Simplex, Mucocutaneous / Immunocompetent Host' group to help and get support from people like you.

Herpes Simplex, Mucocutaneous / Immunocompetent Host News

Task Force: Routine Genital Herpes Screening Not Recommended

Posted 2 Aug 2016 by Drugs.com

TUESDAY, Aug. 2, 2016 – A U.S. federal task force is prepared to recommend that teens, adults and pregnant women not be routinely tested for genital herpes if they don't have signs of infection. About one in every six Americans between the ages of 14 and 49 has genital herpes, according to the U.S. Centers for Disease Control and Prevention. The disease, which is transmitted through vaginal, anal and oral sex, causes symptoms like blisters, discharge, burning and bleeding between periods. Though symptoms can be treated, genital herpes is incurable. In support of its proposed guidelines, the U.S. Preventive Services Task Force says the benefit of routine herpes screening is small, because early treatments aren't likely to make much of a difference. "Because there's no cure, there isn't much doctors and nurses can do for people who don't have symptoms," Dr. Maureen Phipps said in a news ... Read more

Related support groups: Sexually Transmitted Diseases, Cold sores, Herpes Simplex - Suppression, Herpes Simplex, Herpes Simplex Labialis, Herpes Simplex, Mucocutaneous/Immunocompromised Host, Herpes Simplex, Mucocutaneous/Immunocompetent Host, Herpes Simplex Otitis Externa, Herpes Simplex - Prophylaxis

Experimental Genital Herpes Drug Shows Promise

Posted 20 Jun 2016 by Drugs.com

MONDAY, June 20, 2016 – An experimental immune-boosting treatment for genital herpes shows promise, researchers report. The drug, called GEN-003, may reduce both virus activity and the number of days with recurrent herpes in patients. The treatment is given in a series of three injections and appears to last for up to one year, the investigators said. The researchers tested the vaccine on 310 people with a history of chronic, recurrent genital herpes. The findings were to be presented Monday at an American Society for Microbiology meeting in Boston. Research presented at meetings is considered preliminary until published in a peer-reviewed journal. The study was funded by Genocea Biosciences, the Cambridge, Mass.-based company that makes the drug. "GEN-003 is believed to work through a different pathway from most vaccines by recruiting T-cells, which are critical to controlling chronic ... Read more

Related support groups: Sexually Transmitted Diseases, Herpes Simplex - Suppression, Herpes Simplex, Herpes Simplex, Mucocutaneous/Immunocompetent Host, Herpes Simplex - Prophylaxis

New STD Report Finds Some Progress, High Costs for U.S.

Posted 23 Nov 2010 by Drugs.com

MONDAY, Nov. 22 – The approximately 19 million new sexually transmitted disease (STD) infections that occur each year in the United States cost the health care system about $16.4 billion annually, the U.S. Centers for Disease Control and Prevention said in its annual STD report released Monday. The data for 2009 shows a continued high burden of STDs but there are some signs of progress, according to the report, which focuses on chlamydia, gonorrhea and syphilis. The national rate of reported gonorrhea cases stands at 99 cases per 100,000 people, its lowest level since record keeping started in 1941, and cases are declining among all racial/ethnic groups (down 17 percent since 2006). Since 2006, chlamydia infections have increased 19 percent to about 409 per 100,000 people. However, the report suggests that this indicates more people than ever are being screened for chlamydia, which is ... Read more

Related support groups: HIV Infection, Sexually Transmitted Diseases, Chlamydia Infection, Herpes Simplex - Suppression, Trichomoniasis, Herpes Simplex, Human Papilloma Virus, Condylomata Acuminata, Syphilis, Gonococcal Infection - Uncomplicated, Herpes Simplex, Mucocutaneous/Immunocompetent Host, Herpes Simplex, Mucocutaneous/Immunocompromised Host, Herpes Simplex Encephalitis, Cervical Dysplasia, Gonococcal Infection - Disseminated, Tertiary Syphilis, Human Papillomavirus Prophylaxis, Gonococcal Infection, Neurosyphilis, Syphilis - Early

Ask a Question

Further Information

Related Condition Support Groups

Herpes Simplex

Related Drug Support Groups

Valtrex, acyclovir, valacyclovir, famciclovir, Famvir